Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of serum moesin and podocalyxin levels in patients with diabetes mellitus.

Open medicine (Warsaw, Poland)·2026
Same author

Adverse side-effects of antifibrotic drugs in idiopathic pulmonary fibrosis-clarification of several points.

Journal of thoracic disease·2026
Same author

Short-term synbiotic supplementation and intrahepatic triglyceride content assessed by proton MR spectroscopy: a pilot study.

BMC gastroenterology·2026
Same author

Expression pattern of circulating long non-coding RNA <i>GAS5</i> as a novel biomarker in non-small cell lung cancer patients.

Archives of medical science : AMS·2026
Same author

Neurotransmitter Mechanisms of Ketamine and Ketamine-Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABA<sub>A</sub> Contributions.

Brain sciences·2026
Same author

Anti-Desmoglein 3 Avidity Correlates Better With Pemphigus Vulgaris Severity Than Anti-Desmoglein 3 Concentration.

International journal of dermatology·2026

Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419

Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer-A Prospective Pilot Study.

Ivana Simić1, Azra Guzonjić2, Jelena Kotur Stevuljević2

  • 1Medical Affairs, Merck Sharp & Dohme d.o.o., Omladinskih brigada 90a, 11070 Belgrade, Serbia.

Biomedicines
|May 25, 2024
PubMed
Summary
This summary is machine-generated.

Biomarkers like neutrophil-to-lymphocyte ratio (NLR) and Schlafen 11 (SLFN11) can predict chemotherapy response in small cell lung cancer (SCLC). Higher levels of these markers correlate with poorer survival outcomes in SCLC patients.

Keywords:
SCLCSLFN11biomarkerinflammationsPD-L1

More Related Videos

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

13.8K
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.1K

Related Experiment Videos

Last Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419
Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

13.8K
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.1K

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Cancer Therapeutics

Background:

  • Small cell lung cancer (SCLC) remains a challenging diagnosis with limited predictive biomarkers for treatment response.
  • Neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), soluble programmed cell death ligand 1 (sPD-L1), and Schlafen 11 (SLFN11) are potential indicators of systemic inflammation and immune response.

Purpose of the Study:

  • To investigate the correlation between NLR, CRP, sPD-L1, and SLFN11 levels and the response to first-line chemotherapy in SCLC patients.
  • To evaluate the potential of these markers as non-invasive serum biomarkers for predicting treatment outcomes in SCLC.

Main Methods:

  • A cohort of 60 SCLC patients undergoing first-line chemotherapy was studied.
  • Blood samples were collected at baseline, after two cycles, and after four cycles of chemotherapy to measure CRP, sPD-L1, and SLFN11 levels.
  • Neutrophil-to-lymphocyte ratio (NLR) was also assessed.

Main Results:

  • Elevated baseline NLR and SLFN11 levels were associated with shorter survival.
  • In survivors, NLR initially decreased after two cycles but increased after four cycles of chemotherapy.
  • Serum SLFN11 levels increased after two cycles and decreased after four cycles in survivors.
  • Kaplan-Meier analysis identified CRP, NLR, and SLFN11 as significant predictors of survival.
  • A combination of inflammatory markers and SLFN11 predicted significantly lower overall survival.

Conclusions:

  • The combination of inflammatory markers (CRP, NLR) and specific proteins (sPD-L1, SLFN11) shows promise as a non-invasive biomarker for predicting chemotherapy response in SCLC.
  • These biomarkers may help personalize treatment strategies for SCLC patients receiving DNA-damaging agents.